CN114728042A - 用于痴呆的glp-1受体激动剂 - Google Patents
用于痴呆的glp-1受体激动剂 Download PDFInfo
- Publication number
- CN114728042A CN114728042A CN202080076976.0A CN202080076976A CN114728042A CN 114728042 A CN114728042 A CN 114728042A CN 202080076976 A CN202080076976 A CN 202080076976A CN 114728042 A CN114728042 A CN 114728042A
- Authority
- CN
- China
- Prior art keywords
- glp
- dementia
- receptor agonist
- disease
- semaglutide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19207501.8 | 2019-11-06 | ||
| EP19207501 | 2019-11-06 | ||
| EP20186623 | 2020-07-20 | ||
| EP20186623.3 | 2020-07-20 | ||
| PCT/EP2020/081087 WO2021089678A1 (en) | 2019-11-06 | 2020-11-05 | Glp-1 receptor agonists in dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114728042A true CN114728042A (zh) | 2022-07-08 |
Family
ID=73172681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080076976.0A Pending CN114728042A (zh) | 2019-11-06 | 2020-11-05 | 用于痴呆的glp-1受体激动剂 |
Country Status (19)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024179606A1 (zh) * | 2023-03-02 | 2024-09-06 | 甘李药业股份有限公司 | 一种glp-1化合物的医药用途 |
| CN120131965A (zh) * | 2025-04-10 | 2025-06-13 | 瓯江实验室 | Glp-1受体激动剂治疗阿尔茨海默病的用途 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3154744A1 (en) | 2019-11-06 | 2021-05-14 | Sarah FRIEDRICH | Glp-1 receptor agonists in dementia |
| US20230088005A1 (en) * | 2020-01-30 | 2023-03-23 | Eli Lilly And Company | Therapeutic uses of dulaglutide |
| EP4262873A4 (en) * | 2020-12-16 | 2024-12-11 | The Chinese University of Hong Kong | A method for reversing aging brain functional decline |
| CN118510545A (zh) | 2021-12-02 | 2024-08-16 | 哥本哈根大学 | 用于治疗神经退行性疾病的肽-药物缀合物 |
| WO2026096637A1 (en) * | 2024-10-30 | 2026-05-07 | Tiziana Life Sciences Plc | Glp-1 agonists and foralumab combination therapies |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103260608A (zh) * | 2010-12-16 | 2013-08-21 | 诺沃—诺迪斯克有限公司 | 包含glp-1激动剂和n-(8-(2-羟基苯甲酰)氨基)辛酸盐的固体组合物 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| AU3357800A (en) | 1999-02-05 | 2000-08-25 | Emisphere Technologies, Inc. | Method of preparing alkylated salicylamides |
| AU2001275231A1 (en) | 2000-06-02 | 2001-12-11 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
| EP1411968B1 (en) | 2001-07-31 | 2008-09-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glp-1 exendin-4 peptide analogs and uses thereof |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| MX2008001468A (es) | 2005-06-30 | 2008-04-07 | Sod Conseils Rech Applic | Composiciones farmaceuticas del peptido similar al glucagon-1. |
| WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| EP2066337A2 (en) | 2006-08-04 | 2009-06-10 | Amylin Pharmaceuticals, Inc. | Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen |
| MX2009002121A (es) | 2006-09-07 | 2009-05-20 | Hoffmann La Roche | Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico. |
| US8756102B2 (en) * | 2009-11-06 | 2014-06-17 | Edatanetworks Inc. | Method, system, and computer program for attracting local and regional businesses to an automated cause marketing environment |
| US20120329711A1 (en) | 2009-12-16 | 2012-12-27 | Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| AU2012241894B2 (en) | 2011-04-12 | 2015-12-03 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| WO2013004983A1 (en) | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
| HUE049152T2 (hu) * | 2012-07-01 | 2020-09-28 | Novo Nordisk As | Hosszantartó hatású GLP-1 peptidek alkalmazása |
| WO2015155151A1 (en) | 2014-04-07 | 2015-10-15 | Novo Nordisk A/S | Double-acylated glp-1 compounds |
| WO2016198624A1 (en) * | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| US20170112897A1 (en) * | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
| AU2016379403B2 (en) * | 2015-12-23 | 2020-03-12 | The Johns Hopkins University | Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions |
| US20190142905A1 (en) | 2016-04-19 | 2019-05-16 | Ureka Sarl | Peptide-oligourea foldamer compounds and methods of their use |
| GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| CA3154744A1 (en) | 2019-11-06 | 2021-05-14 | Sarah FRIEDRICH | Glp-1 receptor agonists in dementia |
| IL294521A (en) | 2020-02-18 | 2022-09-01 | Novo Nordisk As | glp-1 compounds and their uses |
-
2020
- 2020-11-05 CA CA3154744A patent/CA3154744A1/en active Pending
- 2020-11-05 AU AU2020377469A patent/AU2020377469A1/en active Pending
- 2020-11-05 HU HUE20803489A patent/HUE067514T2/hu unknown
- 2020-11-05 MA MA57599A patent/MA57599B1/fr unknown
- 2020-11-05 KR KR1020227015440A patent/KR20220110731A/ko active Pending
- 2020-11-05 PH PH1/2022/550842A patent/PH12022550842A1/en unknown
- 2020-11-05 RS RS20240863A patent/RS65780B1/sr unknown
- 2020-11-05 EP EP20803489.2A patent/EP4054620B1/en active Active
- 2020-11-05 BR BR112022007721A patent/BR112022007721A2/pt unknown
- 2020-11-05 ES ES20803489T patent/ES2984177T3/es active Active
- 2020-11-05 PL PL20803489.2T patent/PL4054620T3/pl unknown
- 2020-11-05 IL IL291876A patent/IL291876A/en unknown
- 2020-11-05 HR HRP20241052TT patent/HRP20241052T1/hr unknown
- 2020-11-05 JP JP2022521146A patent/JP7670698B2/ja active Active
- 2020-11-05 MX MX2022004779A patent/MX2022004779A/es unknown
- 2020-11-05 EP EP24175772.3A patent/EP4414031A3/en active Pending
- 2020-11-05 WO PCT/EP2020/081087 patent/WO2021089678A1/en not_active Ceased
- 2020-11-05 CN CN202080076976.0A patent/CN114728042A/zh active Pending
- 2020-11-06 TW TW109138851A patent/TWI890704B/zh active
- 2020-11-06 TW TW114103408A patent/TWI923289B/zh active
-
2022
- 2022-05-04 US US17/736,116 patent/US20220280612A1/en not_active Abandoned
-
2023
- 2023-06-12 US US18/208,485 patent/US20230302094A1/en not_active Abandoned
-
2024
- 2024-01-30 US US18/426,412 patent/US20240207364A1/en active Pending
- 2024-12-04 JP JP2024211204A patent/JP2025027130A/ja active Pending
- 2024-12-12 US US18/979,068 patent/US12539326B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103260608A (zh) * | 2010-12-16 | 2013-08-21 | 诺沃—诺迪斯克有限公司 | 包含glp-1激动剂和n-(8-(2-羟基苯甲酰)氨基)辛酸盐的固体组合物 |
Non-Patent Citations (4)
| Title |
|---|
| ANDRE F. BATISTA等: "Neuroprotective Actions of Glucagon‑Like Peptide-1 (GLP-1) Analogues in Alzheimer’s and Parkinson’s Diseases", CNS DRUGS, vol. 33, 3 December 2018 (2018-12-03), pages 209 - 223 * |
| LIPING ZHANG等: "Semaglutide is Neuroprotective and Reduces-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson’s Disease", JOURNAL OF PARKINSON’S DISEASE, vol. 9, 5 February 2019 (2019-02-05), pages 157 - 171, XP055767444, DOI: 10.3233/JPD-181503 * |
| MICHAEL GEJL等: "In Alzheimer’s Disease,6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism:Randomized,Placebo-Controlled,Double-Blind Clinical Trial", FRONT. AGING NEUROSCI, vol. 8, 24 May 2016 (2016-05-24), pages 1 - 10 * |
| YAN YANG等: "Subcutaneous Administration of Liraglutide Ameliorates Alzheimer-Associated Tau Hyperphosphorylation in Rats with Type 2 Diabetes", JOURNAL OF ALZHEIMER’S DISEASE, 24 September 2013 (2013-09-24), pages 637 - 648 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024179606A1 (zh) * | 2023-03-02 | 2024-09-06 | 甘李药业股份有限公司 | 一种glp-1化合物的医药用途 |
| CN120131965A (zh) * | 2025-04-10 | 2025-06-13 | 瓯江实验室 | Glp-1受体激动剂治疗阿尔茨海默病的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| RS65780B1 (sr) | 2024-08-30 |
| WO2021089678A1 (en) | 2021-05-14 |
| EP4054620A1 (en) | 2022-09-14 |
| EP4414031A3 (en) | 2025-02-05 |
| TW202519256A (zh) | 2025-05-16 |
| ES2984177T3 (es) | 2024-10-29 |
| MA57599B1 (fr) | 2024-06-28 |
| MX2022004779A (es) | 2022-06-14 |
| TWI923289B (zh) | 2026-04-21 |
| JP2023500032A (ja) | 2023-01-04 |
| IL291876A (en) | 2022-06-01 |
| EP4054620C0 (en) | 2024-05-29 |
| BR112022007721A2 (pt) | 2022-07-12 |
| KR20220110731A (ko) | 2022-08-09 |
| PL4054620T3 (pl) | 2024-10-14 |
| CA3154744A1 (en) | 2021-05-14 |
| EP4414031A2 (en) | 2024-08-14 |
| TW202118509A (zh) | 2021-05-16 |
| US20220280612A1 (en) | 2022-09-08 |
| EP4054620B1 (en) | 2024-05-29 |
| US12539326B2 (en) | 2026-02-03 |
| US20240207364A1 (en) | 2024-06-27 |
| TWI890704B (zh) | 2025-07-21 |
| HRP20241052T1 (hr) | 2024-11-08 |
| US20250099549A1 (en) | 2025-03-27 |
| JP7670698B2 (ja) | 2025-04-30 |
| PH12022550842A1 (en) | 2023-10-09 |
| US20230302094A1 (en) | 2023-09-28 |
| AU2020377469A1 (en) | 2022-04-28 |
| HUE067514T2 (hu) | 2024-10-28 |
| JP2025027130A (ja) | 2025-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12539326B2 (en) | Methods for treating Alzheimer's disease using semaglutide | |
| US20220226295A1 (en) | Method of treatment with tradipitant | |
| CN108289881A (zh) | 用于治疗纤维化的赛尼克韦罗联合疗法 | |
| US20210330748A1 (en) | Semaglutide for use in medicine | |
| BR112019023557A2 (pt) | Composição farmacêutica compreendendo inibidor de pde9 | |
| EA052078B1 (ru) | Агонисты рецептора glp-1 при лечении деменции | |
| EA046973B1 (ru) | Агонисты рецептора glp-1 при лечении деменции | |
| HK40075453A (en) | Semaglutide in the treatment of alzheimer's dementia | |
| KR20210065950A (ko) | Ccr3-억제제를 사용한 노화 관련 장애 치료를 위한 방법 및 조성물 | |
| HK40053020A (en) | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors | |
| BR122025006435A2 (pt) | Uso de semaglutida para tratamento de esteatose hepática não alcoólica | |
| HK40038946B (en) | Methods of treating subjects having diabetes with chronic kidney disease | |
| US20160022654A1 (en) | Methods of Improving Microvascular Integrity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |